Skip to Main Content

104

Views

2

CrossRef citations to date

0

Altmetric

Original Research

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Thitima Kongnakorn1 Evidence Synthesis, Modeling and Communication, Evidera, London, UKView further author information

,

Murtuza Bharmal2 Global Evidence and Value Development, EMD Serono, Inc. (A business of Merck KGaA, Darmstadt, Germany), Rockland, MA, USACorrespondence[email protected]
View further author information

,

Mairead Kearney3 Global Evidence and Value Development, Merck KGaA, Darmstadt, GermanyView further author information

,

Hemant Phatak4 US Health Economics and Outcomes Research, EMD Serono, Inc. (A business of Merck KGaA, Darmstadt, Germany), Rockland, MA, USAView further author information

,

Agnes Benedict5 Evidence Synthesis, Modeling and Communication, Evidera, Budapest, HungaryView further author information

,

Abhijeet Bhanegaonkar4 US Health Economics and Outcomes Research, EMD Serono, Inc. (A business of Merck KGaA, Darmstadt, Germany), Rockland, MA, USAView further author information

&

Matthew Galsky6 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information